Fig. 1: Characterizations of lung spheroid cell-derived nanodecoys.
a, Representative confocal images of LSCs labelled with ACE2, AQP5 and SFTPC antibodies. DAPI (4′,6-diamidino-2-phenylindole) was used to show nucleus. Three images were taken. b–d, Representative flow cytometry analysis of LSCs (b) and EDCs (c) for ACE2 expression and quantitative results of flow cytometry analysis of EDCs and LSCs for ACE2, EpCAM, CD90, MUC5b and von Willebrand factor (vWF) (d). FITC, fluorescein isothiocyanate. Data are shown as mean ± SD, n = 4 or 6 independent experiments. Statistical analysis was performed by two-way ANOVA with a Tukey post hoc test. See Supplementary Fig. 17 for gating strategies. e, Size measurement of nanodecoys using nanotracking particle analysis (Nanosight). Red shaded area, standard error. f, Western blot of Alix and Calnexin in LSC-nanodecoys and LSCs. g,h, Flow cytometry analysis showing the expressions of ACE2 (g) and the type II pneumocyte marker SFPTC (h) on LSC-nanodecoys. See Supplementary Fig. 17 for gating strategies. i, Measurement of ACE2 numbers on both cells and nanodecoys. HEK indicates HEK293. Data are shown as mean ± SD, n = 3 independent experiments. j,k, TEM images showing naked nanodecoys (j) and enlarged figure (k). l,m, TEM images showing spike S1-bound nanodecoys (l) and enlarged figure (m). Spike S1 was detected using gold-nanoparticle-labelled secondary antibodies with diameters of 10 nm. Scale bar in j and i, 200 nm; scale bar in k and m, 20 nm. Cartoon pictures (insets in j and l) were created with BioRender.com.
